AgingResearch.NewsJoin free

Biohaven

CompanyUnited States

Biohaven develops one asset, in phase 3 (BHV-1300 in Graves' disease). Mostly protein or enzyme acting on inflammation and ASGR1; based in the United States.

1
Asset
Furthest stage
Phase 3
0
Trials
1
Signal

Pipeline

1

  • BHV-1300

    Bispecific extracellular pan-IgG degrader targeting IgG to asialoglycoprotein receptors

    Phase 3, Protein or enzyme, Inflammation, ASGR1, Graves' disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies6

Intelligence